One broad-spectrum drug to treat ~90% of known and unknown pathogenic viruses. NV-387 entering Phase II for monkeypox and ODD designation approved by US FDA for Measles… A timely opportunity to invest in the development of a revolutionary treatment that is safe, nontoxic, and effective even as variants emerge.
NanoViricides, Inc. (NYSE: NNVC) is a clinical-stage biopharmaceutical company pioneering nanoviricide® technology with virus-targeted nanomachines that bind, encapsulate, and destroy virus particles before they infect cells. Lead candidate NV-387 has completed Phase I with no adverse events, is advancing into Phase II, and has been granted ODD designation by the US FDA for measles. By addressing multiple high-impact viral diseases through a single broad-spectrum drug, NanoViricides positions itself as a key player in global antiviral preparedness and innovation.
NanoViricides has developed nanoviricides® capable of binding up to 90–95% of known and unknown pathogenic viruses. Lead candidate NV-387 targets RSV, COVID-19, Influenza/Bird Flu, Smallpox/MPox, Measles, and more. Another nanoviricide, NV-HHV-1, targets Shingles and other Herpes viruses. Additional nanoviricides are in development against Dengue, Rabies, and Ebola/Marburg.
NV-387 completed Phase I human clinical trials with no reported adverse events, demonstrating excellent safety and tolerability.
Does not rely on the patient's immune system, potentially benefiting pediatric and geriatric patients where vaccines fall short.
NanoViricide copies the unique receptor site used by each virus, not the virus itself, thereby making it effective against the virus and its variants.
NanoViricides is one of the few pre-revenue biotechs to own its own multi-product, cGMP-compliant drug manufacturing facility; debt-free.
NV-387 can be manufactured in blisterpacks for easy use and is stable at room temperature for two years to enable easy transportation and storage.
Ten programs across two drug substances — NV-387 and NV-HHV-1 — with multiple indications progressing toward Phase I and Phase II, and with a deep preclinical bench in DNA and RNA viral cures.
Phase 2 Mpox trial for NV-378 continues to progress towards initiation.
Add NNVC to your TradingView watchlist for native price alerts, catalyst tracking, and a persistent view of the chart while the Phase II story unfolds.
NanoViricides, Inc. is a NYSE-American listed publicly traded company (stock symbol: NNVC).
This is not an offering memorandum and should not be construed as such. It is provided as a non-confidential document for informational purposes only.
NanoViricides, Inc. (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials as therapeutics against a number of different viruses. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. All of our drug candidates are based on broad and exclusive worldwide licenses in perpetuity from TheraCour Pharma, Inc. for the development of drugs to combat viral infections of Human Coronaviruses, Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Viruses (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu viruses, Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis virus, viruses causing viral Conjunctivitis (a disease of the eye). The Company's technology is based on broad, exclusive, sub-licensable, perpetual field licenses to all drugs developed in the licensed field areas (virus indications) from TheraCour Pharma, Inc. The Company obtains additional licenses after determining that it intends to pursue a drug candidate in the licensed field into commercialization. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, covering all drugs for the licensed application, as established at its foundation in 2005.
This document contains forward-looking statements that reflect the current expectation of NanoViricides, Inc. (the "Company") regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements.
The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.
Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
© All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE-Amer.: NNVC)
